Compare
Copper blends compared: GLOW, KLOW and the 50 mg GHK-Cu, TB-500 and BPC-157 blend
Published October 9, 2026 · Facts checked October 9, 2026
Short answer
In all three blends GHK-Cu is the only copper carrier. GLOW 70 mg holds 50 mg GHK-Cu with 10 mg each of BPC-157 and TB-500 (Thymosin Beta-4, full-length); KLOW 80 mg holds the same three plus 10 mg KPV; the 50 mg blend holds 35 mg GHK-Cu, 10 mg TB-500 and 5 mg BPC-157. Which one fits is a question of which peptides, in which proportions, your work calls for — and the theoretical copper content follows: 11.29 %, 9.88 % and 11.07 % of the declared peptide mass.
Side by side
| GLOW | KLOW | GHK-Cu + TB-500 + BPC-157 | |
|---|---|---|---|
| Vial strengths | 42 mg, 70 mg | 80 mg | 50 mg |
| Peptides per vial | 70 mg: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 (42 mg: split confirmed with the quote) | 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV | 35 mg GHK-Cu, 10 mg TB-500, 5 mg BPC-157 |
| GHK-Cu share of declared mass | 71.4 % (70 mg) | 62.5 % | 70.0 % |
| Theoretical copper | 11.29 % (70 mg) | 9.88 % | 11.07 % |
| Peptides without copper | BPC-157, TB-500 | BPC-157, TB-500, KPV | TB-500, BPC-157 |
| Catalogue codes | GLOW42, GLOW70 | KLOW80 | BBG50 |
| Kit | 10 vials of one strength, from 1 kit | 10 vials, from 1 kit | 10 vials, from 1 kit |
How to choose
- Need KPV in the same vial: KLOW is the only one of the three that carries it.
- Need more TB-500 than BPC-157: the 50 mg blend has 10 mg against 5 mg; GLOW and KLOW have the two in equal amounts.
- Need the most GHK-Cu per vial: GLOW 70 mg and KLOW 80 mg each carry 50 mg; the 50 mg blend carries 35 mg.
- Need the copper peptide on its own: GHK-Cu comes in 50 and 100 mg vials, AHK-Cu in 20, 50 and 100 mg.
- Need a split that is not listed: ask sales; the quote states what can be supplied.
What the GHK-Cu share does to the copper figures
Theoretical copper in a blend is the GHK-Cu mass times the copper share of the pure 1:1 complex (63.546 ÷ 401.91 = 15.81 %), divided by the declared mass of the vial. For GLOW 70 mg that is 50 × 15.81 % ÷ 70 = 11.29 %; KLOW spreads the same 50 mg over 80 mg, so 9.88 %. On a COA, as-is copper reads lower than these ceilings for the same reasons as GHK-Cu alone: acetate and water.
Sources: PubChem CID 165429100
The peptides besides GHK-Cu
- BPC-157: a 15-residue peptide, C62H98N16O22, 1419.5 g/mol (PubChem CID 9941957).
- KPV: the tripeptide Lys-Pro-Val, C16H30N4O4, 342.44 g/mol (PubChem CID 125672).
- TB-500 (Thymosin Beta-4, full-length): the 43-residue peptide, C212H350N56O78S, 4963.5 g/mol (PubChem CID 16132341) — the form in all three blends.
Sources: PubChem CID 9941957 · PubChem CID 125672 · PubChem CID 16132341
What the literature has studied
Our catalogue's literature review found no published study of these peptides combined — neither the three-peptide mix of GLOW and the 50 mg blend nor the four-peptide mix of KLOW. The single peptides have been studied on their own, in animal and cell models: GHK-Cu in rat wound-chamber and irradiated-flap models (Maquart 1993; Parker 2013), BPC-157 in a rat small-bowel resection model (Sever 2009), thymosin beta-4 in mouse skin-wound models (Philp 2003), and KPV in intestinal cell lines and mouse colitis models (Dalmasso 2008). None of them tested a blend, and this page draws no conclusion for one.
Sources: Maquart et al., J Clin Invest 1993;92(5):2368-76 · Parker et al., Otolaryngol Head Neck Surg 2013;149(3):384-9 · Sever et al., Dig Dis Sci 2009;54(10):2070-83 · Philp et al., Wound Repair Regen 2003;11(1):19-24 · Dalmasso et al., Gastroenterology 2008;134(1):166-78
What comes with each batch
Each batch of every blend has its own COA with HPLC purity, MS identity, bacterial endotoxin and fill. Our release specification confirms identity for each declared peptide and assays each against its own label claim.
Questions
- What is the difference between GLOW and KLOW?
- KLOW adds 10 mg KPV to the GHK-Cu, BPC-157 and TB-500 of GLOW, in an 80 mg vial against GLOW's 70 mg.
- Which copper blend has the most GHK-Cu?
- GLOW 70 mg and KLOW 80 mg both carry 50 mg; the 50 mg blend carries 35 mg. As a share of the vial, GLOW 70 mg is highest at 71.4 %.
- What is BBG50?
- Our catalogue code for the 50 mg vial holding 35 mg GHK-Cu, 10 mg TB-500 and 5 mg BPC-157.
- Has the GLOW combination itself been studied?
- Our catalogue's literature review found no published study of GHK-Cu, BPC-157 and TB-500 combined, with or without KPV; the single peptides have been studied on their own.
References
- PubChem CID 165429100 — GHK copper complex (C14H22CuN6O4, 401.91) — formula and molecular weight of the neutral 1:1 complex
- PubChem CID 9941957 — BPC-157 (C62H98N16O22, 1419.5) — BPC-157 identity, formula and molecular weight (blend component)
- PubChem CID 125672 — KPV, Lys-Pro-Val (C16H30N4O4, 342.44) — KPV identity, formula and molecular weight (blend component)
- PubChem CID 16132341 — thymosin beta-4, full length (C212H350N56O78S, 4963.5) — TB-500 in our copper blends: full-length thymosin beta-4 (owner 10-03 and 10-09; pep-sku blend_tb = full-length)
- Maquart et al., J Clin Invest 1993;92(5):2368-76 — GHK-Cu in a rat wound-chamber model — GHK-Cu studied alone in implanted wound chambers in rats
- Parker et al., Otolaryngol Head Neck Surg 2013;149(3):384-9 — GHK-Cu in an irradiated rat flap model — GHK-Cu studied alone, applied to irradiated skin flaps in rats
- Sever et al., Dig Dis Sci 2009;54(10):2070-83 — BPC-157 in a rat short-bowel model — BPC-157 studied alone in rats after small-bowel resection
- Philp et al., Wound Repair Regen 2003;11(1):19-24 — thymosin beta-4 and its actin-binding peptide in mouse skin-wound models — thymosin beta-4 and a synthetic peptide of its actin-binding domain studied in db/db and aged mice
- Dalmasso et al., Gastroenterology 2008;134(1):166-78 — KPV uptake through PepT1 — KPV studied alone in intestinal cell lines and mouse colitis models; uptake through the PepT1 transporter
Products and related guides